PharmGen Science, Inc.

A004720

KR7004720009

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
5,290 ^KRW	+1.15%		-3.64%	-14.68%

2023	PharmGen Science, Inc.(KOSE:A004720) dropped from S&P Global BMI Index	CI
2023	PharmGen Science, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Kim, Soo-Kyoung sold 1.69% stake in Wooridul Pharmaceuticals Limited for KRW 1.1 billion.

January 15, 2013 at 09:30 am IST

Kim, Soo-Kyoung sold 1.69% stake in Wooridul Pharmaceuticals Limited (KOSE:A004720) for KRW 1.1 billion on January 15, 2013. Kim, Soo-Kyoung sold 1.3 million shares for KRW 826 each. Pursuant to the transaction, Kim, Soo-Kyoung owns 8.9 million shares of Wooridul.

Kim, Soo-Kyoung completed the sale of 1.69% stake in Wooridul Pharmaceuticals Limited (KOSE:A004720) on January 15, 2013.

Latest news about PharmGen Science, Inc.

PharmGen Science, Inc.(KOSE:A004720) dropped from S&P Global BMI Index	18/23/18	CI
PharmGen Science, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
PharmGen Science Inc. announced that it has received KRW 20 billion in funding from Meritz Securities Co., Ltd.	11/22/11	CI
PharmGen Science Inc. announced that it expects to receive KRW 20 billion in funding from Meritz Securities Co., Ltd.	03/22/03	CI
PharmGen Science Inc. announced that it has received KRW 30 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited	11/21/11	CI
PharmGen Science Inc. announced that it expects to receive KRW 30 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited	17/21/17	CI
Wooridul Pharmaceutical Limited announced that it has received KRW 20 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited	27/20/27	CI
Wooridul Pharmaceutical Limited announced that it expects to receive KRW 20 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited	11/20/11	CI
Wooridul Pharmaceutical Limited(KOSE:A004720) added to S&P Global BMI Index	21/20/21	CI
Wooridul Pharmaceutical Limited cancelled the acquisition of 11.6% stake in Access Bio, Inc. from Youngho Choi.	03/20/03	CI
HD Fund signed a stock transfer agreement to acquire 6.4% stake in Wooridul Pharmaceutical Limited from Soo-Kyung Kim for KRW 12 billion.	03/20/03	CI
Access Bio, Inc. announced that it has received KRW 9.999999142 billion in funding from Wooridul Pharmaceutical Limited	21/19/21	CI
Wooridul Pharmaceutical Limited signed a contract to acquire 11.6% stake in Access Bio, Inc. from Youngho Choi for KRW 17 billion.	04/19/04	CI
Access Bio, Inc. announced that it expects to receive KRW 9.999999142 billion in funding from Wooridul Pharmaceutical Limited	03/19/03	CI
Wooridul Pharmaceutical Limited announced that it has received KRW 20 billion in funding from Choeun Mutual Savings Bank, Investment Arm, Hana Capital Co., Ltd., and other investors	01/18/01	CI
Wooridul Pharmaceutical Limited announced that it expects to receive KRW 20 billion in funding from Choeun Mutual Savings Bank, Investment Arm, Hana Capital Co., Ltd., and other investors.	24/18/24	CI
Miev Co., Ltd. announced that it has received KRW 1 billion in funding from Wooridul Pharmaceutical Limited	20/17/20	CI
Miev Co., Ltd. announced that it expects to receive KRW 1 billion in funding from Wooridul Pharmaceutical Limited	18/17/18	CI
Wooridul Pharmaceutical Limited(KOSE:A004720) dropped from S&P Global BMI Index	18/17/18	CI
Wooridul Pharmaceutical Limited(KOSE:A004720) added to S&P Global BMI Index	19/16/19	CI
Wooridul Pharmaceutical Limited announced that it has received KRW 10 billion in funding from Sejong Mutual Savings Bank Co.,Ltd., Investment Arm and other investors.	30/16/30	CI
Wooridul Pharmaceutical Limited announced that it expects to receive KRW 10 billion in funding from Sejong Mutual Savings Bank Co.,Ltd., Investment Arm, and other investors.	28/16/28	CI
Wooridul Pharmaceutical Limited announced that it has received KRW 4 billion in funding from KTB Network Co., Ltd. and other investors.	03/15/03	CI
Wooridul Pharmaceutical Limited announced that it expects to receive KRW 4 billion in funding from KTB Network Co., Ltd. and other investors.	30/15/30	CI
Wooridul Pharmaceutical Limited announced that it has received KRW 6.4 billion in funding.	29/14/29	CI

Chart PharmGen Science, Inc.

Duration

Period

More charts

Company Profile

PharmGen Science Inc, formerly Wooridul Pharmaceutical Ltd, is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Companyâs products include antiepileptic agents, anti-inflammatory agents, antiphlogistic agents, central nervous system agents, urinary agents, antihistamine agents, antivirus agents, agents for bones, agents for livers, calcium agents, antibiotics, diabetes agents, respiratory agents, as well as over-the-counter (OTC) drugs, obesity drugs, health food and others. In addition, the Company is also engaged in the manufacturing, wholesale and retail distribution of functional cosmetics. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
PHARMGEN SCIENCE, INC.	-14.68%	6.94Cr
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	4.2TCr
OTSUKA HOLDINGS CO., LTD.	+22.40%	2.23TCr
SANDOZ GROUP AG	+18.48%	1.52TCr
CIPLA LIMITED	+16.12%	1.4TCr
ZYDUS LIFESCIENCES LIMITED	+45.12%	1.21TCr
ONO PHARMACEUTICAL CO., LTD.	-9.58%	679.6Cr
THE MEDICINES COMPANY	-0.05%	678.76Cr
STADA ARZNEIMITTEL	-8.87%	572.55Cr
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	549.33Cr